Rimm Lab Members

RimmLabGroup 2014

Leadership


David L Rimm

Professor of Pathology Director of Pathology Tissue Services Director of Translational Pathology

Professor of Pathology and of Medicine (Medical Oncology); Director of Pathology Tissue Services; Director of Translational Pathology

Biography

Dr. David Rimm, is a Professor in the Department of Pathology at the Yale University School of Medicine. He completed an MD-PhD at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. He is board certified in Anatomic Pathology and Cytopathology. At Yale since 1994, Dr. Rimm is the Director of Yale Pathology Tissue Services and the Yale Tissue Microarray Facility. He is a member of the Executive...

Dr. David Rimm, is a Professor in the Department of Pathology at the Yale University School of Medicine. He completed an MD-PhD at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. He is board certified in Anatomic Pathology and Cytopathology. At Yale since 1994, Dr. Rimm is the Director of Yale Pathology Tissue Services and the Yale Tissue Microarray Facility. He is a member of the Executive Team in Pathology and serves as the Director of Translational Pathology. His lab group (15 researchers) focuses on quantitative pathology using the AQUA® technology invented in his lab with projects related to predicting response to therapy in breast cancer and predicting recurrence or metastasis in melanoma and lung cancer. He is currently supported by 9 grants from both public and private sources. He serves as a reviewer for the NIH and was a charter member of the Cancer Biomarkers Study Section. He is an editorial board member for 7 pathology journals and a member of the pathology committee for TransALLTO and TEACH (cooperative groups or therapeutic clinical trials). He is an author of over 275 peer-reviewed papers and 8 patents and was the scientific co-founder of HistoRx, a digital pathology company (sold to Genoptix in 2012) and Metamark Genetics, a prognostic determinant company.

Read More
       

Members


Yalai Bai

Associate Research Scientist in Pathology

See more...

Jason Brown

PhD Student

Determining Biomarkers that Predict Response to Neoadjuvant Chemotherapy in Breast Cancer  For locally advanced breast cancers, neoadjuvant chemotherapy is often administered prior to surgical intervention.  Despite its value in facilitating breast conserving surgery, this treatment modality does not improve overall survival compared to adjuvant chemotherapy.  Biomarkers that predict response to therapy can better guide treatment strategy and avoid adverse effects from cytotoxic...

See more...


Daniel Carvajal

Postdoctoral Associate in Pathology

See more...

Joseph McLaughlin

Clinical Fellow in Medicine (Medical Oncology)

See more...


Lauren Moore

PhD Student: Pharmacology

Investigation of Molecular Mechanisms that Govern Taxane Resistance   The clinical application of biomarkers has greatly reduced the mortality rates associated with breast cancer; however, there is an urgent need for the identification and validation of novel biomarkers that can more effectively predict response to taxane chemotherapy. My project focuses on identifying molecular targets that may play a role in molecular mechanism of taxane resistance primarily...

See more...

Vasiliki Pelekanou

Associate Research Scientist in Pathology

Dr Vasiliki Pelekanou received her MD (2004) and PhD (2008) from the University of Crete School of Medicine in Greece. She then completed her Post-Doctoral Fellowship at Institut Jules Bordet-Free University of Brussels, Belgium. She is trained in Pathology and Cytopathology (Free University of Brussels and University of Crete). She is member of international scientific associations and ad hoc reviewer in 7 scientific journals. She holds 4 international...

See more...


Kurt Schalper

Associate Research Scientist in Pathology

See more...

Hallie Wimberly

PhD Student

Estrogen receptor beta and alternatively spliced variants in estrogen signaling and relevance to clinical response to endocrine therapy   Estrogen receptor (ER) alpha is not the only mediator of estrogen signaling. Other ER isoforms and alternatively spliced variants may be crucial in mediating cellular response to estrogen and may provide insight into sensitivity to endocrine therapy in breast cancer patients. However the current literature is riddled with conflicting...

See more...